Original Research Article

Phospho- β -catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues

Joel Pinczewski¹, Rebecca Obeng^{2,3}, Craig L. Slingluff, Jr.^{3,4,5}, and Victor H. Engelhard^{2,3,5}.

¹Department of Pathology, ²Department of Microbiology, Immunology and Cancer Biology, ³Beirne Carter Center for Immunology Research, ⁴Department of Surgery, ⁵UVA Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, 22908.

Running title: Phosphorylated β -catenin in melanoma

Address correspondence to Craig L. Slingluff, Jr., M.D. Department of Surgery, University of Virginia School of Medicine, P.O. Box 800709, Charlottesville, VA, 22908-0709

Abstract:

β -catenin (β cat) is an important downstream effector in the Wnt signaling pathway and plays an important role in the development and progression of many cancers including melanoma. β cat expression is regulated by GSK-3 β -mediated phosphorylation at positions 33, 37 and 41. In normal cells, phosphorylation at these sites triggers proteasomal degradation, which in turn prevents accumulation of free cytoplasmic β cat. In cancer cells, stabilized β -catenin translocates into the nucleus, where it associates with TCF/Lef proteins to activate transcription of genes that promote tumorigenesis and metastasis. It has been suggested that nuclear phospho- β cat (p β cat) staining may be diagnostically useful in differentiating primary from metastatic melanoma. Also, a p β cat peptide (residues 30-39, p33) is naturally presented by melanoma cells as a T-cell target. We evaluated the expression of pS33- β cat in primary and metastatic melanoma tissues by immunohistochemistry. pS33- β cat was detected in primary and metastatic melanomas and was most commonly cytoplasmic and almost never exclusively nuclear. Interestingly, staining with pS33- β cat and pS33/37/T41- β cat antibodies was most intense in mitotic melanoma cells, consistent with prior studies demonstrating changes in the level of β cat during cell division. We observed no significant differences in p β cat staining location or intensity between primary and metastatic melanomas, suggesting that p β cat may have limited diagnostic or prognostic utility in melanoma. However, the high expression in dividing cells suggests promise as an immunotherapeutic target.

Introduction

β -catenin (β cat) forms a downstream portion of the highly conserved canonical Wnt cell signaling pathway. As a member of this pathway, β cat has a pivotal role in embryogenesis and in cell signaling in later life. Mutations in β cat or the proteins that regulate it (e.g., the adenomatous polyposis coli (APC) protein), which lead to accumulation of β cat, are associated with the development and progression of a variety of benign and malignant neoplasms, including familial adenomatous polyposis, Gardner's syndrome, and colorectal cancer(1-4). However, mutations resulting in β cat accumulation are also associated with other malignancies including gastric and endometrial adenocarcinomas, hepatocellular cancers, hepatoblastomas, and melanomas(2, 5). In unstimulated adult cells, β cat is located mainly on the cytoplasmic side of the cell membrane, where it associates with E-cadherin as part of adherens junctions(6). Free cytoplasmic β cat is maintained at a low level by formation of a destruction complex involving β cat, glycogen synthase kinase-3 β (GSK-3 β), casein kinase 1a (CK1a), APC and Axin(7). This leads to sequential phosphorylation of the complexed β cat at T41, S37, and S33 by GSK-3 β , targeting it for destruction by the ubiquitin/proteasome pathway. Signaling through the Wnt pathway results in a different fate for β cat(8). In this setting, free β cat is protected from phosphorylation and is able to accumulate in the cytoplasm. This build-up in cytoplasmic β cat leads to its eventual translocation to the nucleus where it complexes with T-cell factor (TCF)/ lymphoid enhancer-binding factor (LEF) and other molecules and effects transcription of genes involved in tumorigenesis and metastasis such as c-myc and metalloprotease(9-11).

Zarling et al have identified a β cat peptide spanning amino acids 30-39 and phosphorylated at S33 on melanoma, which is presented by human HLA-A2 molecules as an antigen for cytotoxic T cells(12). This suggests that N-terminal phosphorylation of β cat occurs in melanoma cells and

the resulting peptide may be a target for cancer immunotherapy. Phosphorylation at S33 only occurs after phosphorylation at residues 37 and 41; so, detection of pS33- β cat identifies the tri-phosphorylated form of β cat. pS33- β cat has not been shown to have transcriptional activity, but some authors have reported that the presence of cytoplasmic and nuclear pS33- β cat staining in malignant cells has diagnostic and prognostic significance. Nakopolou found that cytoplasmic pS33- β cat staining was associated with an improved outcome in breast cancer, whereas high levels of nuclear pS33- β cat staining were associated with a poor outcome(13). Kielhorn found that most primary and metastatic melanomas did not stain with an antibody detecting pS33- β cat(14). When present, however, pS33- β cat staining was always nuclear and was more commonly seen and more intense in metastatic melanoma than in primary melanomas. On the basis of this and Kaplan-Meier survival curves, Kielhorn suggested that nuclear pS33- β cat staining and its intensity might serve as a useful diagnostic and prognostic marker in melanoma(14).

Activation of the Wnt/ β cat pathway in melanoma has been reported to have immunological significance, with reduction in immune cell infiltrates in melanomas with Wnt/ β cat activation(15). This heightens interest in understanding the relevance of pS33- β cat expression in melanoma, coupled with the finding that a pS33- β cat peptide is an epitope recognized by human CD8⁺ T cells. The relevance of pS33- β cat as a T cell target requires understanding whether pS33- β cat is expressed in normal tissues from vital organs and whether it is selectively expressed by melanoma cells compared to such normal tissues. β cat is expressed in normal tissues including heart and lung, but regulation of β cat phosphorylation is complex enough that expression levels of β cat may not predict expression of pS33- β cat. To our knowledge, the expression of pS33- β cat in human normal tissues has not been assessed. We hypothesized that pS33- β cat would be expressed at higher levels in melanoma metastases than in normal tissues. Thus, in the present study, we performed

immunohistochemistry (IHC) studies to determine the breadth of pS33- β cat expression in primary and metastatic melanoma tissues as well as in normal human tissues. We also compared the levels and intracellular locations of pS33- β cat staining in primary and metastatic melanoma specimens as well as pS33- β cat staining in normal tissues to re-evaluate the potential use of pS33- β cat as a diagnostic and prognostic indicator for melanoma.

Material and Methods

Melanoma tissues for analysis in this study included samples of formalin-fixed and paraffin-embedded (FFPE) specimens from a melanoma tissue microarray (TMA), preparation of which has been described previously(16), plus additional FFPE samples obtained from the archives of the Department of Anatomic Pathology at the University of Virginia (IRB-HSR 15237 and 10598). These included fifteen primary melanomas and forty-three metastatic melanomas. Included among the metastatic melanoma specimens were lung (n=5), heart (n=1) and liver (n=1) specimens that contained melanoma metastases and evaluable portions of non-malignant (“normal”) tissue from the same organs that had been invaded. Cells of the human melanoma cell line SLM2(17) growing in log phase also were pelleted, formalin fixed, paraffin embedded, and then sectioned for the study. Tissue sections were deparaffinized in xylene and rehydrated by sequential passage through graded alcohol/water solutions. Heat-induced antigen retrieval was performed using Vector’s Target Retrieval Solution (Vector Laboratories, Burlingame, CA), pH 6 at 100°C for 20 min.

Working concentrations of antibodies to β cat (1:500, Epitomics, Burlingame, CA # 1247-1) and phospho- β cat (pS33- β cat 1:200, Santa Cruz, Santa Cruz, CA # SC-16743-R; pS33/37/T41- β cat 1:1200, Cell Signaling Technology, Danvers, MA, #9561) were used. In some assays, a 13-

mer pS33- β cat blocking phosphopeptide (QSYLDpSGIHSGAT, Genscript, Piscataway, NJ) was added to anti- β cat and anti-pS33- β cat antibodies (1:200), giving a final peptide concentration of 50 μ g/ml, and incubated for 30 min prior to being added to slides for blocking. The slides stained for pS33- β cat were incubated overnight at 4 degrees, and slides stained for β cat were incubated for 30 min at room temperature. Expression was detected using Vector's ImmPRESS peroxidase kit and visualized with Vector's ImmPACT™ AEC substrate. Slides were then counterstained with Gill's hematoxylin. Negative control slides were prepared by omitting the primary antibodies. Slides were scanned using an Aperio CS slide scanner (Aperio, Vista, CA) and were analyzed using the Aperio Imagescope "positive pixel count" analytical software algorithm. The resulting data were used to calculate total staining density per unit area.

Results

The specificity of the polyclonal pS33- β cat antibody was tested by staining four normal tissues -- liver, placenta, spleen and kidney -- with and without pre-incubation with a corresponding pS33- β cat phosphopeptide as a control. As a further control, a commercial anti- β cat antibody was also used. All four normal tissues stained strongly with both the pS33- β cat and β cat specific antibodies (**Figure 1**). Staining with the pS33- β cat antibody was significantly reduced by pre-incubation with pS33- β cat phosphopeptide. Pre-incubation with the blocking phosphopeptide had minimal effect on β cat antibody staining.

To assess the diagnostic and prognostic value of pS33- β cat, we compared the intensity and staining location of the pS33- β cat antibody in TMA blocks containing 15 primary and 43 metastatic melanomas. All fifteen primary melanomas (100%) had cytoplasmic staining (**Figure 2**). In addition, 2/15 (15%) had combined membranous and cytoplasmic staining and 3/15 (20%)

had combined nuclear and cytoplasmic staining. In the single remaining case, membranous, cytoplasmic, and nuclear staining were all evident concurrently. Among the metastatic melanomas, 36/43 (84%) had cytoplasmic staining. Nuclear staining was observed in 6/43 cases (14%). However, in all but one of these cases the nuclear staining was combined with cytoplasmic staining. Therefore, isolated nuclear staining was only observed in one case (2%). Membranous staining was evident in 5/43 cases (11%). These consisted of 4 tumors with combined nuclear and cytoplasmic staining and 1 with isolated membranous staining. A complete lack of staining was observed in 7/43 cases (16%).

To explore whether there were differences in the level of p β cat in tumors and normal tissues that might have relevance in the diagnosis and treatment strategies for melanoma patients, we compared staining in melanoma metastases versus adjacent lung, liver, and heart tissue that did not contain melanoma. Whole sections of lung, liver and heart tissue, containing both metastatic melanoma and adjacent uninvolved tissue, were stained with the pS33- β cat antibody. Metastatic melanoma in the lung tissue mainly had cytoplasmic staining but also included one case with minimal staining and another with predominantly membranous staining (**Figure 3**). The most intense staining occurred in the uninvolved lung tissue and in respiratory epithelia. As shown in **Figure 4**, cardiac myocytes had higher staining intensities than the metastatic melanoma in heart tissue, with the most intense staining occurring in the intercalated discs. In liver tissue (**Figure 5**), there was only very weak staining for both metastatic melanoma and adjacent uninvolved hepatocytes (**Figure 5**).

Phosphorylation of pS33 requires prior phosphorylation of S37 and T41 by GSK-3 β ¹⁹. We therefore hypothesized that an antibody to pS33- β cat would produce comparable staining to an antibody to pS33/37/T41- β cat. We stained an SLM-2 melanoma cell line with both antibodies

(Figure 6). Indeed, the two antibodies produced comparable staining. For both antibodies, staining was largely cytoplasmic, with a minority of cells having combined nuclear/cytoplasmic staining. Nuclear staining was somewhat more evident with the pS33/37/T41- β cat antibody than the pS33- β cat antibody. One particularly striking finding was that mitotic cells showed much more intense staining with both p β cat antibodies than melanoma cells without mitotic figures.

Discussion

We have found that melanoma metastases express pS33- β cat at varied levels and that the most common staining pattern in melanoma cells was cytoplasmic, both for the primary melanomas and for metastases. In contrast to expectation, there also was high expression of pS33- β cat in multiple normal tissues, including liver, placenta, spleen, kidney, lung, and heart. The validity of the antibody stain was confirmed by blocking with a specific phospho- β -catenin peptide. When evaluating lung and heart tissue containing melanoma metastases, the expression of pS33- β cat was higher in the surrounding normal tissue than in melanoma cells of the same specimen. A striking finding, however, was that the intensity of pS33- β cat staining in melanoma cells was greatest in actively dividing cells.

β cat serves an important function in embryogenesis and tissue development and is also an important downstream mediator of the development and progression of cancer. The N-terminus is of particular interest since this region contains phosphorylation sites that are critical for regulation of cellular levels of β cat that in turn affect the protein's transcriptional activity. It has been suggested that p β cat expression may have diagnostic and/or prognostic value and specifically that nuclear staining of melanoma by an antibody to pS33- β cat, and the intensity of this staining might be useful as diagnostic markers to differentiate primary melanoma from metastatic melanoma and

as prognostic markers in melanoma(14). In contrast to prior work(14), we found that cytoplasmic pS33- β cat staining was the most common staining pattern. In fact, exclusively nuclear staining only occurred in a single melanoma, and a complete lack of staining was also uncommon. Our finding of widespread cytoplasmic pS33- β cat staining in melanoma is much more in keeping with what might be expected if GSK-3 β activity is maintained in the majority of melanomas. Kielhorn acknowledged that their finding was paradoxical, and suggested that it might be due to a defect in the proteasomal breakdown machinery in melanoma cells(14). However, while this would explain why p β cat might build up in the cells, it does not explain why the protein would be exclusively found in the nucleus. Our findings using both pS33- β cat antibodies are consistent with expectation that the most common location of p β cat is the cytoplasm.

Kielhorn also reported that more intense nuclear staining with the pS33/37/T41- β cat antibody was associated with metastatic melanoma(14). However, we found no significant differences between the intensity of either nuclear or cytoplasmic staining in the primary and metastatic melanomas. To evaluate whether p β cat expression differed between melanomas and normal tissues in vital organs, we selected tissue blocks containing metastatic melanoma and attached uninvolved tissue from the invaded organ to exclude tissue handling as a source of variability. Although the number of metastatic melanoma tissues tested in this study was limited, we found that cytoplasmic p β cat staining was less intense in the metastatic melanomas than in the uninvolved tissues in most cases. Although this could be due to a decrease in β cat phosphorylation in the metastatic cells, it seems unlikely since mutations in the N-terminus of β cat or in the components of the destruction complex such as APC are rare in melanoma(2, 5). Alternatively, these findings may also reflect an overall decrease in the level of β cat in melanoma, as previous studies have shown(18-20). This may be due to enhanced degradation of the protein as opposed to

decreased gene expression since increased levels of mRNA have been found in metastatic melanoma tissues compared to primary melanoma(21). It is also possible that because melanoma cells are actively in cycle, p β cat is degraded more rapidly in melanoma cells than in normal tissues. β cat has been shown to accumulate in the cytoplasm during the cell cycle, with peak levels evident in the G2/M phase(22). Degradation of β cat, by phosphorylation, is needed for the cells to progress from the G2 phase through the M-phase(22). This correlates with our finding that mitotic figures in melanoma tissues show increased pS33- β cat staining intensity compared to cells not in the M phase of the cell cycle. Thus, the increased frequency of cell division in melanoma may account for an overall low level of p β cat while the increased levels observed in normal tissues may reflect steady state levels and a decreased rate of degradation owing to decreased frequency in cell division.

To our knowledge, the expression of p β cat in normal tissues has not been reported elsewhere. We found that normal heart and lung tissue both have high levels of pS33- β cat, with the most intense staining in the intercalated discs of myocytes and respiratory epithelial cells, respectively. β cat forms part of the adherens junction in intercalated discs. β cat has previously been reported to accumulate in the intercalated discs of myocytes in patients with hypertrophic cardiomyopathy(23). Furthermore, Maher et al have reported that p β cat and components of the destruction complex (axin, APC2, and GSK-3 β) can localize to areas of cell-cell contact that are distinct from cadherin-catenin complexes at the cell membrane and facilitate phosphorylation of β cat, thereby leading to speculation about the possible role of β cat in cell fate during development and tissue morphogenesis(24). Thus, the high-level expression of pS33- β cat at the intercalated discs of the myocytes may be due to accumulation and phosphorylation of β cat at that site in normal tissues. Collectively, the results from our assessment of primary and metastatic melanomas

as well as normal tissues suggest that pS33- β cat levels and localization are not suitable as either a diagnostic or a prognostic marker in melanoma.

One further interesting finding from our work was that p β cat staining was sharply increased in mitotic melanoma cells with antibodies both to pS33- β cat and to pS33/37/T41- β cat. This may be due to an increase in cytoplasmic β cat during mitosis, which is subsequently phosphorylated by GSK-3 β leading to increased p β cat production. Indeed it has been shown that β cat and APC, a key component of the destruction complex, accumulates in the cytoplasm during the cell cycle, with the highest level of β cat being detected at the G2/M phase followed by a sharp decrease in β cat levels when cells enter the G1 phase(22). Additionally, the cells arrest in the G2 phase and undergo apoptosis if degradation of β cat is blocked by inhibiting GSK-3 β , suggesting that phosphorylation of β cat at S33/37/T41 is necessary for cells to progress through the M phase. Thus, the strong pS33- β cat staining we observed in the mitotic melanoma cells is likely indicative of the imminent degradation of β cat in melanoma cells in this phase of the cell cycle. This finding may be useful in assessing whether p β cat could be targeted for cancer immunotherapy.

Overall, our results indicate that the pS33- β cat and pS33/37/T41- β cat antibodies produce comparable staining patterns in primary and metastatic melanoma. Cytoplasmic p β cat is most predominant in the tumor cells. We did not detect differences between p β cat expression between primary and metastatic melanomas; so, our data do not support use of p β cat antibodies for diagnostic or prognostic purposes in melanoma. Interestingly, we observed strong p β cat staining in mitotic melanoma cells. Given the results of other studies demonstrating that degradation of β cat is necessary for progression through the M phase, the phosphorylated peptide derived from β cat that was identified on melanoma cell lines may be an interesting target for immunotherapy for melanoma patients.

Acknowledgements

This work was supported by the United States Public Health Service Grants R01CA134060 and R01CA190665 (VHE), T32AI007496 (JP), F31CA119954 (RCO), and T32GM007267 (RCO). We thank the University of Virginia Biorepository Tissue Resource Facility (supported by USPHS Cancer Center Support Grant P30 CA44579) for tissue sectioning and Donna H. Deacon for technical assistance.

Disclosures/Conflict of Interest

RCO and VHE acknowledge conflicting financial interests as shareholders in Agenus, Inc. CLS is an inventor on patents for peptides used in cancer vaccines held by the University of Virginia Licensing and Ventures Group but not for phosphopeptides. CLS also has current or prior consultant roles for Celldex, CureVac and Castle Biosciences, and has institutional support from Celldex, Polynoma, GSK, Merck, 3M, Theraclion and Immatics.

References Cited

1. Takemaru KI, Ohmitsu M, Li FQ. An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics. In: Klussman E, Scott, J., editor. Protein-Protein Interactions as New Drug Targets Handbook Exp Pharmacol. ed. Berlin, Heidelberg: Springer; 2008. p. 261-84.
2. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. *Am J Pathol* 1999;154:325-9.
3. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. *Proc Natl Acad Sci U S A* 2009;106:1193-8.
4. Ghosh N, Hossain U, Mandal A, Sil PC. The Wnt signaling pathway: a potential therapeutic target against cancer. *Ann N Y Acad Sci* 2019;1443:54-74.
5. Pollock PM, Hayward N. Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines. *Melanoma Res* 2002;12:183-6.
6. Ozawa M, Kemler R. Molecular organization of the uvomorulin-catenin complex. *J Cell Biol* 1992;116:989-96.
7. Behrens J, Jerchow BA, Würtele M, Grimm J, Asbrand C, Wirtz R, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. *Science* 1998;280:596-9.
8. Itoh K, Krupnik VE, Sokol SY. Axis determination in *Xenopus* involves biochemical interactions of axin, glycogen synthase kinase 3 and beta-catenin. *Current biology : CB* 1998;8:591-4.
9. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. *Oncogene* 1999;18:2883-91.
10. Hamada F, Tomoyasu Y, Takatsu Y, Nakamura M, Nagai S, Suzuki A, et al. Negative regulation of Wingless signaling by D-axin, a *Drosophila* homolog of axin. *Science* 1999;283:1739-42.
11. Polakis P. Wnt signaling in cancer. *Cold Spring Harbor perspectives in biology* 2012;4.
12. Zarling AL, Polefrone JM, Evans AM, Mikesch LM, Shabanowitz J, Lewis ST, et al. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. *Proc Natl Acad Sci U S A* 2006;103:14889-94.
13. Nakopoulou L, Mylona E, Papadaki I, Kavantzias N, Giannopoulou I, Markaki S, et al. Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* 2006;19:556-63.
14. Kielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, Camp RL, et al. Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome. *International journal of cancer Journal international du cancer* 2003;103:652-6.
15. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β -catenin signalling prevents anti-tumour immunity. *Nature* 2015;523:231-5.
16. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. *Cancer Res* 2012;72:1070-80.

17. Kierstead LS, Ranieri E, Olson W, Brusica V, Sidney J, Sette A, et al. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4⁺ T cells. *British Journal of Cancer* 2001;85:1738-45.
18. Sanders DS, Blessing K, Hassan GA, Bruton R, Marsden JR, Jankowski J. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. *Molecular pathology* : MP 1999;52:151-7.
19. Kageshita T, Hamby CV, Ishihara T, Matsumoto K, Saida T, Ono T. Loss of beta-catenin expression associated with disease progression in malignant melanoma. *The British journal of dermatology* 2001;145:210-6.
20. Maelandsmo GM, Holm R, Nesland JM, Fodstad Ø, Flørenes VA. Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. *Clin Cancer Res* 2003;9:3383-8.
21. Demunter A, Libbrecht L, Degreef H, De Wolf-Peeters C, van den Oord JJ. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. *Modern pathology* : an official journal of the United States and Canadian Academy of Pathology, Inc 2002;15:454-61.
22. Olmeda D, Castel S, Vilaró S, Cano A. Beta-catenin regulation during the cell cycle: implications in G2/M and apoptosis. *Molecular biology of the cell* 2003;14:2844-60.
23. Masuelli L, Bei R, Sacchetti P, Scappaticci I, Francalanci P, Albonici L, et al. Beta-catenin accumulates in intercalated disks of hypertrophic cardiomyopathic hearts. *Cardiovascular research* 2003;60:376-87.
24. Maher MT, Flozak AS, Stocker AM, Chenn A, Gottardi CJ. Activity of the beta-catenin phosphodestruction complex at cell-cell contacts is enhanced by cadherin-based adhesion. *J Cell Biol* 2009;186:219-28.

Figure Legends

Figure 1. Phospho- β catenin in normal human tissues. Total staining density per unit area for normal liver, lung, spleen and placenta stained with antibodies to (A) pS33- β cat and (B) β cat, with pre-incubation with pS33- β cat blocking phosphopeptide (p β cat-Block and β cat-Block) or without blocking (p β cat-nb and β cat-nb).

Figure 2. Expression and localization of phospho- β -catenin in primary (A, B) and metastatic (C, D) melanomas. (A, C) The proportion with nuclear (N), cytoplasmic (C), membranous (M) staining, combinations (MCN, MC, CN), or no staining (X). (B, D) The extent of staining in each region is shown per patient tumor based on scoring of 0 to 3 in each cellular area (N, C, and M). The intensity of staining was graded from 0 (no staining) to 3+ (heavy staining).

Figure 3. p β cat staining of lung tissue and melanoma metastasis from the same patient. Representative sections of pS33- β cat stained tissue from five cases of metastatic melanoma to lung at a 75x magnification. (A, C, E) staining of uninvolved respiratory epithelium from three tumors. (B, D, F) the corresponding metastatic melanomas from these cases.

Figure 4. p β cat staining in heart tissue with melanoma metastasis. Representative section of pS33- β cat stained heart tissue from a patient with metastatic melanoma to heart at a 30x magnification. The uninvolved heart tissue is on the left side of the figure and has weak cytoplasmic staining with more intense staining of the intercalated discs. The metastatic melanoma on the right side of the figure has no significant staining.

Figure 5. p β cat in liver tissue with melanoma metastasis. Representative section of pS33- β cat stained liver (20x magnification) containing a melanoma metastasis. Neither the uninvolved liver (left side of figure) nor the melanoma (right side of figure) had significant staining for pS33- β cat.

Figure 6. p β cat staining of melanoma cell block with two antibodies. A cell block of the SLM2 melanoma cell line was stained with antibodies to pS33- β cat (left panel) and pS33/37/T41- β cat (right panel). Staining for both antibodies was predominantly cytoplasmic but also included some nuclear staining with a slight predilection for nuclear staining with the pS33/37/T41- β cat antibody. Mitotic cells stained much more intensely than adjacent non-dividing cells.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6